{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:39:25Z","timestamp":1790314765346,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["G0800318"],"award-info":[{"award-number":["G0800318"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MC\/PC12022"],"award-info":[{"award-number":["MC\/PC12022"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/L023040\/1"],"award-info":[{"award-number":["MR\/L023040\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/K002406\/1"],"award-info":[{"award-number":["MR\/K002406\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["FS\/13\/48\/30453"],"award-info":[{"award-number":["FS\/13\/48\/30453"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["FS\/18\/52\/33808"],"award-info":[{"award-number":["FS\/18\/52\/33808"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["FS\/08\/061\/25740"],"award-info":[{"award-number":["FS\/08\/061\/25740"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["FS\/18\/13\/33281"],"award-info":[{"award-number":["FS\/18\/13\/33281"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["206632\/Z\/17\/Z"],"award-info":[{"award-number":["206632\/Z\/17\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pulmonary arterial hypertension (PAH) is a rare but fatal disease. Current treatments increase life expectancy but have limited impact on the progressive pulmonary vascular remodelling that drives PAH. Osteoprotegerin (OPG) is increased within serum and lesions of patients with idiopathic PAH and is a mitogen and migratory stimulus for pulmonary artery smooth muscle cells (PASMCs). Here, we report that the pro-proliferative and migratory phenotype in PASMCs stimulated with OPG is mediated via the Fas receptor and that treatment with a human antibody targeting OPG can attenuate pulmonary vascular remodelling associated with PAH in multiple rodent models of early and late treatment. We also demonstrate that the therapeutic efficacy of the anti-OPG antibody approach in the presence of standard of care vasodilator therapy is mediated by a reduction in pulmonary vascular remodelling. Targeting OPG with a therapeutic antibody is a potential treatment strategy in PAH.<\/jats:p>","DOI":"10.1038\/s41467-019-13139-9","type":"journal-article","created":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T11:03:48Z","timestamp":1573815828000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4317-5738","authenticated-orcid":false,"given":"Nadine D.","family":"Arnold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7199-364X","authenticated-orcid":false,"given":"Josephine A.","family":"Pickworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2953-2521","authenticated-orcid":false,"given":"Laura E.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana A.","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Casbolt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3228-2172","authenticated-orcid":false,"given":"Adam T.","family":"Braithwaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3953-8812","authenticated-orcid":false,"given":"James","family":"Iremonger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis","family":"Renshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Germaschewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"McCourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Bland-Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4732-470X","authenticated-orcid":false,"given":"Hager","family":"Kowash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2128-2081","authenticated-orcid":false,"given":"Abdul G.","family":"Hameed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7847-4500","authenticated-orcid":false,"given":"Alexander M. K.","family":"Rothman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria G.","family":"Frid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0717-4551","authenticated-orcid":false,"given":"A. A.","family":"Roger Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6712-2481","authenticated-orcid":false,"given":"Holly R.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Southwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5700-9792","authenticated-orcid":false,"given":"Nicholas W.","family":"Morrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4762-8623","authenticated-orcid":false,"given":"David C.","family":"Crossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7788-1852","authenticated-orcid":false,"given":"Moira K. B.","family":"Whyte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6918-6411","authenticated-orcid":false,"given":"Kurt R.","family":"Stenmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Kiely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6552-0339","authenticated-orcid":false,"given":"Sheila E.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4192-9505","authenticated-orcid":false,"given":"Allan","family":"Lawrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,15]]},"reference":[{"key":"13139_CR1","doi-asserted-by":"publisher","first-page":"D42","DOI":"10.1016\/j.jacc.2013.10.032","volume":"62","author":"MM Hoeper","year":"2013","unstructured":"Hoeper, M. M. et al. Definitions and diagnosis of pulmonary hypertension. J. Am. Coll. Cardiol. 62, D42\u2013D50 (2013).","journal-title":"J. Am. Coll. Cardiol."},{"key":"13139_CR2","doi-asserted-by":"publisher","first-page":"D4","DOI":"10.1016\/j.jacc.2013.10.025","volume":"62","author":"RM Tuder","year":"2013","unstructured":"Tuder, R. M. et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J. Am. Coll. Cardiol. 62, D4\u2013D12 (2013).","journal-title":"J. Am. Coll. Cardiol."},{"key":"13139_CR3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nrcardio.2011.87","volume":"8","author":"RT Schermuly","year":"2011","unstructured":"Schermuly, R. T., Ghofrani, H. A., Wilkins, M. R. & Grimminger, F. Mechanisms of disease: pulmonary arterial hypertension. Nat. Rev. Cardiol. 8, 443\u2013455 (2011).","journal-title":"Nat. Rev. Cardiol."},{"key":"13139_CR4","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1172\/JCI33452","volume":"118","author":"M Rabinovitch","year":"2008","unstructured":"Rabinovitch, M. Molecular pathogenesis of pulmonary arterial hypertension. J. Clin. Invest. 118, 2372\u20132379 (2008).","journal-title":"J. Clin. Invest."},{"key":"13139_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.molmed.2016.11.005","volume":"23","author":"AAR Thompson","year":"2017","unstructured":"Thompson, A. A. R. & Lawrie, A. Targeting vascular remodeling to treat pulmonary arterial hypertension. Trends Mol. Med 23, 31\u201345 (2017).","journal-title":"Trends Mol. Med"},{"key":"13139_CR6","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1183\/09031936.00078411","volume":"39","author":"J Hurdman","year":"2012","unstructured":"Hurdman, J. et al. ASPIRE registry: assessing the spectrum of pulmonary hypertension identified at a REferral centre. Eur. Respir. J. 39, 945\u2013955 (2012).","journal-title":"Eur. Respir. J."},{"key":"13139_CR7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1164\/rccm.201201-0164OC","volume":"186","author":"E Stacher","year":"2012","unstructured":"Stacher, E. et al. Modern age pathology of pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med 186, 261\u2013272 (2012).","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"13139_CR8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/nm.3877","volume":"21","author":"L Long","year":"2015","unstructured":"Long, L. et al. Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. Nat. Med. 21, 777\u2013785 (2015).","journal-title":"Nat. Med."},{"key":"13139_CR9","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1172\/JCI24838","volume":"115","author":"RT Schermuly","year":"2005","unstructured":"Schermuly, R. T. et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J. Clin. Invest. 115, 2811\u20132821 (2005).","journal-title":"J. Clin. Invest."},{"key":"13139_CR10","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1161\/CIRCULATIONAHA.106.681718","volume":"115","author":"SI Said","year":"2007","unstructured":"Said, S. I. et al. Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation 115, 1260\u20131268 (2007).","journal-title":"Circulation"},{"key":"13139_CR11","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.phrs.2011.03.003","volume":"63","author":"D Shao","year":"2011","unstructured":"Shao, D., Park, J. E. S. & Wort, S. J. The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension. Pharm. Res. 63, 504\u2013511 (2011).","journal-title":"Pharm. Res."},{"key":"13139_CR12","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1084\/jem.20112716","volume":"209","author":"AG Hameed","year":"2012","unstructured":"Hameed, A. G. et al. Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension. J. Exp. Med. 209, 1919\u20131935 (2012).","journal-title":"J. Exp. Med."},{"key":"13139_CR13","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2353\/ajpath.2008.070395","volume":"172","author":"A Lawrie","year":"2008","unstructured":"Lawrie, A. et al. Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension. Am. J. Pathol. 172, 256\u2013264 (2008).","journal-title":"Am. J. Pathol."},{"key":"13139_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4103\/2045-8932.94819","volume":"2","author":"R Condliffe","year":"2012","unstructured":"Condliffe, R. et al. Serum osteoprotegerin is increased and predicts survival in idiopathic pulmonary arterial hypertension. Pulm. Circ. 2, 21\u201327 (2012).","journal-title":"Pulm. Circ."},{"key":"13139_CR15","doi-asserted-by":"publisher","first-page":"e001591","DOI":"10.1161\/CIRCGENETICS.116.001591","volume":"10","author":"D Jia","year":"2017","unstructured":"Jia, D. et al. Osteoprotegerin disruption attenuates HySu-induced pulmonary hypertension through integrin \u03b1v\u03b23\/FAK\/AKT pathway suppression. Circ. Cardiovasc. Genet. 10, e001591 (2017).","journal-title":"Circ. Cardiovasc. Genet."},{"key":"13139_CR16","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/j.ajpath.2011.06.037","volume":"179","author":"A Lawrie","year":"2011","unstructured":"Lawrie, A. et al. Paigen diet-fed apolipoprotein E knockout mice develop severe pulmonary hypertension in an interleukin-1-dependent manner. Am. J. Pathol. 179, 1693\u20131705 (2011).","journal-title":"Am. J. Pathol."},{"key":"13139_CR17","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1161\/ATVBAHA.109.188185","volume":"29","author":"O Ovchinnikova","year":"2009","unstructured":"Ovchinnikova, O. et al. Osteoprotegerin promotes fibrous cap formation in atherosclerotic lesions of ApoE-deficient mice\u2013brief report. Arterioscler. Thromb. Vasc. Biol. 29, 1478\u20131480 (2009).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"13139_CR18","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1161\/ATVBAHA.113.301755","volume":"33","author":"A Callegari","year":"2013","unstructured":"Callegari, A. et al. Bone marrow\u2013 or vessel wall\u2013derived osteoprotegerin is sufficient to reduce atherosclerotic lesion size and vascular calcification significance. Arterioscler. Thromb. Vasc. Biol. 33, 2491\u20132500 (2013).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"13139_CR19","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1161\/ATVBAHA.114.304587","volume":"34","author":"CS Moran","year":"2014","unstructured":"Moran, C. S., Jose, R. J., Biros, E. & Golledge, J. Osteoprotegerin deficiency limits angiotensin II-induced aortic dilatation and rupture in the apolipoprotein E-knockout mouse. Arterioscler. Thromb. Vasc. Biol. 34, 2609\u20132616 (2014).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"13139_CR20","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","volume":"93","author":"DL Lacey","year":"1998","unstructured":"Lacey, D. L. et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165\u2013176 (1998).","journal-title":"Cell"},{"key":"13139_CR21","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1164\/rccm.200810-1662OC","volume":"180","author":"M Toshner","year":"2009","unstructured":"Toshner, M. et al. Evidence of dysfunction of endothelial progenitors in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 180, 780\u2013787 (2009).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"13139_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/2045-8932.78095","volume":"1","author":"ME Yeager","year":"2011","unstructured":"Yeager, M. E., Frid, M. G. & Stenmark, K. R. Progenitor cells in pulmonary vascular remodeling. Pulm. Circ. 1, 3\u201316 (2011).","journal-title":"Pulm. Circ."},{"key":"13139_CR23","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1161\/01.RES.0000243584.45145.3f","volume":"99","author":"KR Stenmark","year":"2006","unstructured":"Stenmark, K. R., Fagan, K. A. & Frid, M. G. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ. Res. 99, 675\u2013691 (2006).","journal-title":"Circ. Res."},{"key":"13139_CR24","doi-asserted-by":"publisher","first-page":"e99890","DOI":"10.1371\/journal.pone.0099890","volume":"9","author":"J Martin-Ramirez","year":"2014","unstructured":"Martin-Ramirez, J. et al. Individual with subclinical atherosclerosis have impaired proliferation of blood outgrowth endothelial cells, which can be restored by statin therapy. PLoS ONE 9, e99890 (2014).","journal-title":"PLoS One"},{"key":"13139_CR25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/bioinformatics\/btn577","volume":"25","author":"AL Tarca","year":"2009","unstructured":"Tarca, A. L. et al. A novel signaling pathway impact analysis. Bioinformatics 25, 75\u201382 (2009).","journal-title":"Bioinformatics"},{"key":"13139_CR26","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1172\/JCI83361","volume":"126","author":"AMK Rothman","year":"2016","unstructured":"Rothman, A. M. K. et al. MicroRNA-140-5p and SMURF1 regulate pulmonary arterial hypertension. J. Clin. Invest. 126, 2495\u20132508 (2016).","journal-title":"J. Clin. Invest."},{"key":"13139_CR27","doi-asserted-by":"publisher","first-page":"28504","DOI":"10.1074\/jbc.M204851200","volume":"277","author":"DW Leaman","year":"2002","unstructured":"Leaman, D. W. et al. Identification of X-linked inhibitor of apoptosis-associated factor-1 as an interferon-stimulated gene that augments TRAIL Apo2L-induced apoptosis. J. Biol. Chem. 277, 28504\u201328511 (2002).","journal-title":"J. Biol. Chem."},{"key":"13139_CR28","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nbt.2825","volume":"32","author":"E-C Lee","year":"2014","unstructured":"Lee, E.-C. et al. Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery. Nat. Biotechnol. 32, 356\u2013363 (2014).","journal-title":"Nat. Biotechnol."},{"key":"13139_CR29","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa1209655","volume":"369","author":"H-A Ghofrani","year":"2013","unstructured":"Ghofrani, H.-A. et al. PATENT-1 Study Group. Riociguat for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 369, 330\u2013340 (2013).","journal-title":"N. Engl. J. Med."},{"key":"13139_CR30","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1213917","volume":"369","author":"T Pulido","year":"2013","unstructured":"Pulido, T. et al. SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N. Engl. J. Med. 369, 809\u2013818 (2013).","journal-title":"N. Engl. J. Med."},{"key":"13139_CR31","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMra040291","volume":"351","author":"M Humbert","year":"2004","unstructured":"Humbert, M., Sitbon, O. & Simonneau, G. Treatment of pulmonary arterial hypertension. N. Engl. J. Med. 351, 1425\u20131436 (2004).","journal-title":"N. Engl. J. Med."},{"key":"13139_CR32","doi-asserted-by":"publisher","first-page":"14363","DOI":"10.1074\/jbc.273.23.14363","volume":"273","author":"JG Emery","year":"1998","unstructured":"Emery, J. G. et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273, 14363\u201314367 (1998).","journal-title":"J. Biol. Chem."},{"key":"13139_CR33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1365-2567.2009.03058.x","volume":"127","author":"C Falschlehner","year":"2009","unstructured":"Falschlehner, C., Schaefer, U. & Walczak, H. Following TRAIL\u2019s path in the immune system. Immunology 127, 145\u2013154 (2009).","journal-title":"Immunology"},{"key":"13139_CR34","doi-asserted-by":"publisher","first-page":"5259","DOI":"10.4049\/jimmunol.0902797","volume":"185","author":"T Ikeda","year":"2010","unstructured":"Ikeda, T. et al. Dual effects of TRAIL in suppression of autoimmunity: the inhibition of Th1 cells and the promotion of regulatory T cells. J. Immunol. 185, 5259\u20135267 (2010).","journal-title":"J. Immunol."},{"key":"13139_CR35","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1189\/jlb.0211062","volume":"90","author":"EE McGrath","year":"2011","unstructured":"McGrath, E. E. et al. TNF-related apoptosis-inducing ligand (TRAIL) regulates inflammatory neutrophil apoptosis and enhances resolution of inflammation. J. Leukoc. Biol. 90, 855\u2013865 (2011).","journal-title":"J. Leukoc. Biol."},{"key":"13139_CR36","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1136\/thoraxjnl-2011-200863","volume":"67","author":"EE McGrath","year":"2012","unstructured":"McGrath, E. E. et al. Deficiency of tumour necrosis factor-related apoptosis-inducing ligand exacerbates lung injury and fibrosis. Thorax 67, 796\u2013803 (2012).","journal-title":"Thorax"},{"key":"13139_CR37","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1084\/jem.20120983","volume":"209","author":"K Steinwede","year":"2012","unstructured":"Steinwede, K. et al. TNF-related apoptosis-inducing ligand (TRAIL) exerts therapeutic efficacy for the treatment of pneumococcal pneumonia in mice. J. Exp. Med. 209, 1937\u20131952 (2012).","journal-title":"J. Exp. Med."},{"key":"13139_CR38","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1084\/jem.20122235","volume":"209","author":"CA Benedict","year":"2012","unstructured":"Benedict, C. A. & Ware, C. F. TRAIL: not just for tumors anymore? J. Exp. Med. 209, 1903\u20131906 (2012).","journal-title":"J. Exp. Med."},{"key":"13139_CR39","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3390\/diseases2030260","volume":"2","author":"SH Dawson","year":"2014","unstructured":"Dawson, S. H., Arnold, N. D., Pickworth, J. A., Francis, S. E. & Lawrie, A. TRAIL deficient mice are protected from sugen\/hypoxia induced pulmonary arterial hypertension. Diseases 2, 260\u2013273 (2014).","journal-title":"Diseases"},{"key":"13139_CR40","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","volume":"12","author":"N Bucay","year":"1998","unstructured":"Bucay, N. et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12, 1260\u20131268 (1998).","journal-title":"Genes Dev."},{"key":"13139_CR41","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","volume":"89","author":"WS Simonet","year":"1997","unstructured":"Simonet, W. S. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309\u2013319 (1997).","journal-title":"Cell"},{"key":"13139_CR42","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.cytogfr.2013.06.001","volume":"24","author":"M Baud\u2019huin","year":"2013","unstructured":"Baud\u2019huin, M. et al. Osteoprotegerin: multiple partners for multiple functions. Cytokine Growth Factor Rev. 24, 401\u2013409 (2013).","journal-title":"Cytokine Growth Factor Rev."},{"key":"13139_CR43","doi-asserted-by":"publisher","first-page":"L740","DOI":"10.1152\/ajplung.00284.2002","volume":"285","author":"S Zhang","year":"2003","unstructured":"Zhang, S. et al. Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. Am. J. Physiol. Lung Cell Mol. Physiol. 285, L740\u2013L754 (2003).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"13139_CR44","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ijcard.2011.09.004","volume":"165","author":"S Akagi","year":"2013","unstructured":"Akagi, S. et al. Prostaglandin I2 induces apoptosis via upregulation of Fas ligand in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. Int. J. Cardiol. 165, 499\u2013505 (2013).","journal-title":"Int. J. Cardiol."},{"key":"13139_CR45","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1161\/CIRCRESAHA.118.313911","volume":"124","author":"AJ Sweatt","year":"2019","unstructured":"Sweatt, A. J. et al. Discovery of distinct immune phenotypes using machine learning in pulmonary arterial hypertension. Circ. Res. 124, 904\u2013919 (2019).","journal-title":"Circ. Res."},{"key":"13139_CR46","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1165\/ajrcmb.11.6.7946395","volume":"11","author":"NF Voelkel","year":"1994","unstructured":"Voelkel, N. F., Tuder, R. M., Bridges, J. & Arend, W. P. Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline. Am. J. Respir. Cell Mol. Biol. 11, 664\u2013675 (1994).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"13139_CR47","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/jnr.490290405","volume":"29","author":"GT Capone","year":"1991","unstructured":"Capone, G. T., Bendotti, C., Oster-Granite, M. L. & Coyle, J. T. Developmental expression of the gene encoding growth-associated protein 43 (Gap43) in the brains of normal and aneuploid mice. J. Neurosci. Res. 29, 449\u2013460 (1991).","journal-title":"J. Neurosci. Res."},{"key":"13139_CR48","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s004180000243","volume":"115","author":"M Takahashi","year":"2001","unstructured":"Takahashi, M. et al. Localization of human airway trypsin-like protease in the airway: an immunohistochemical study. Histochem. Cell Biol. 115, 181\u2013187 (2001).","journal-title":"Histochem. Cell Biol."},{"key":"13139_CR49","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.2353\/ajpath.2006.051054","volume":"168","author":"J Chamberlain","year":"2006","unstructured":"Chamberlain, J. et al. Interleukin-1beta and signaling of interleukin-1 in vascular wall and circulating cells modulates the extent of neointima formation in mice. Am. J. Pathol. 168, 1396\u20131403 (2006).","journal-title":"Am. J. Pathol."},{"key":"13139_CR50","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1164\/rccm.201103-0412OC","volume":"184","author":"L Ciuclan","year":"2011","unstructured":"Ciuclan, L. et al. A novel murine model of severe pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 184, 1171\u20131182 (2011).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"6","key":"13139_CR51","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1172\/JCI23203","volume":"115","author":"M. S. McMurtry","year":"2005","unstructured":"McMurtry,\u00a0M. S. et al. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J. Clin. Invest. 115, 1479\u20131491\u00a0(2005).","journal-title":"Journal of Clinical Investigation"},{"issue":"4","key":"13139_CR52","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1378\/chest.126.4.1313","volume":"126","author":"Denis Chemla","year":"2004","unstructured":"Chemla, D. et al. New formula for predicting mean pulmonary artery pressure using systolic pulmonary artery pressure. Chest 126, 1313\u20131317\u00a0(2004).","journal-title":"Chest"},{"key":"13139_CR53","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1172\/JCI118031","volume":"96","author":"JD Wohrley","year":"1995","unstructured":"Wohrley, J. D. et al. Hypoxia selectively induces proliferation in a specific subpopulation of smooth muscle cells in the bovine neonatal pulmonary arterial media. J. Clin. Invest. 96, 273\u2013281 (1995).","journal-title":"J. Clin. Invest."},{"key":"13139_CR54","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"13139_CR55","doi-asserted-by":"publisher","first-page":"D199","DOI":"10.1093\/nar\/gkt1076","volume":"42","author":"M Kanehisa","year":"2014","unstructured":"Kanehisa, M. et al. Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res. 42, D199\u2013D205 (2014).","journal-title":"Nucleic Acids Res."},{"key":"13139_CR56","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"key":"13139_CR57","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1161\/01.RES.0000176025.57706.1e","volume":"97","author":"A Lawrie","year":"2005","unstructured":"Lawrie, A. et al. Interdependent serotonin transporter and receptor pathways regulate S100A4\/Mts1, a gene associated with pulmonary vascular disease. Circ. Res. 97, 227\u2013235 (2005).","journal-title":"Circ. Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13139-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13139-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13139-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T02:07:13Z","timestamp":1671242833000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13139-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,15]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["13139"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-13139-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,15]]},"assertion":[{"value":"21 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.L.\/The University of Sheffield has been granted intellectual property around the area of targeting OPG for the treatment of PAH (GB2510524 \/ US9334327 \/ JP2014532637) and is a founding Director of PH Therapeutics Ltd, a University of Sheffield Spin-out company. J.C., V.G., M.M. and P.B.-W. are employees of Kymab Ltd and hold share options in the company. Kymab has filed intellectual property (GB1701416.8) around the characteristics of a therapeutic human anti-osteoprotegerin antibody with A.L. named as an inventor. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5183"}}